5L2I:
reference: Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance., Chen P, Lee N, Hu W, Xu M, Ferre RA, Lam H, Bergqvist S, Solowiej J, Diehl W, He YA, Yu X, Nagata A, VanArsdale T, Murray BW, Mol Cancer Ther. 2016 Aug 5. pii: molcanther.0300.2016. PMID: 27496135

This OCA Structure page
uses Jmol, developed by the Jmol Development Team (documentation).